A director at InvoCare Limited bought 4,000 shares at 10.630AUD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
INVOCARE (AU), a company active in the Personal Products & Services industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date July 2, 2021, the closing price was AUD 11.23 and its pote...
Wide-moat-rated Invocare has commenced its earnings recovery with a strong start to fiscal 2019. We have not changed our AUD 16.00 per share fair value estimate, to which the firm currently trades at a slight discount. Gross revenue is up 8% on the previous corresponding period, or pcp, which is tracking marginally ahead of our full-year 6% forecast. The stronger-than-expected growth mainly reflects an improvement in market conditions, with the number of deaths reverting towards the long-term tr...
Wide-moat-rated Invocare has commenced its earnings recovery with a strong start to fiscal 2019. We have not changed our AUD 16.00 per share fair value estimate, to which the firm currently trades at a slight discount. Gross revenue is up 8% on the previous corresponding period, or pcp, which is tracking marginally ahead of our full-year 6% forecast. The stronger-than-expected growth mainly reflects an improvement in market conditions, with the number of deaths reverting towards the long-term tr...
Wide-moat-rated Invocare has commenced its earnings recovery with a strong start to fiscal 2019. We have not changed our AUD 16.00 per share fair value estimate, to which the firm currently trades at a slight discount. Gross revenue is up 8% on the previous corresponding period, or pcp, which is tracking marginally ahead of our full-year 6% forecast. The stronger-than-expected growth mainly reflects an improvement in market conditions, with the number of deaths reverting towards the long-term tr...
We recommend wide-moat-rated Invocare’s shareholders apply for the full allocation of shares offered in the share purchase plan, or SPP. The SPP issue price will be the lower of AUD 14.00 per share (the price at which new shares were issued under the institutional placement), and the volume weighted average price, or VWAP, of InvoCare shares traded on the ASX over the five trading days up to and including the day on which the SPP offer is closed. The offer opens for eligible shareholder on Mon...
We recommend wide-moat-rated Invocare’s shareholders apply for the full allocation of shares offered in the share purchase plan, or SPP. The SPP issue price will be the lower of AUD 14.00 per share (the price at which new shares were issued under the institutional placement), and the volume weighted average price, or VWAP, of InvoCare shares traded on the ASX over the five trading days up to and including the day on which the SPP offer is closed. The offer opens for eligible shareholder on Mon...
We recommend wide-moat-rated Invocare’s shareholders apply for the full allocation of shares offered in the share purchase plan, or SPP. The SPP issue price will be the lower of AUD 14.00 per share (the price at which new shares were issued under the institutional placement), and the volume weighted average price, or VWAP, of InvoCare shares traded on the ASX over the five trading days up to and including the day on which the SPP offer is closed. The offer opens for eligible shareholder on Mon...
Wide-moat InvoCare is undertaking an institutional placement to raise AUD 65 million, and an additional share purchase plan, or SPP, capped at AUD 20 million. The institutional placement is underwritten with a AUD 13.30 floor price, a 7% discount to the last closing price, and a 17% discount to our unchanged AUD 16.00 per share fair value estimate. The SPP is not underwritten and will be priced at the lesser of the issue price of the Institutional Placement, or the volume weighted average price,...
Wide-moat InvoCare is undertaking an institutional placement to raise AUD 65 million, and an additional share purchase plan, or SPP, capped at AUD 20 million. The institutional placement is underwritten with a AUD 13.30 floor price, a 7% discount to the last closing price, and a 17% discount to our unchanged AUD 16.00 per share fair value estimate. The SPP is not underwritten and will be priced at the lesser of the issue price of the Institutional Placement, or the volume weighted average price,...
Wide-moat InvoCare is undertaking an institutional placement to raise AUD 65 million, and an additional share purchase plan, or SPP, capped at AUD 20 million. The institutional placement is underwritten with a AUD 13.30 floor price, a 7% discount to the last closing price, and a 17% discount to our unchanged AUD 16.00 per share fair value estimate. The SPP is not underwritten and will be priced at the lesser of the issue price of the Institutional Placement, or the volume weighted average price,...
Wide-moat InvoCare is undertaking an institutional placement to raise AUD 65 million, and an additional share purchase plan, or SPP, capped at AUD 20 million. The institutional placement is underwritten with a AUD 13.30 floor price, a 7% discount to the last closing price, and a 17% discount to our unchanged AUD 16.00 per share fair value estimate. The SPP is not underwritten and will be priced at the lesser of the issue price of the Institutional Placement, or the volume weighted average price,...
Wide-moat rated Invocare reported a soft, albeit well flagged fiscal 2018 result. Operating EBITDA declined by 4% to AUD 119 million, in line with our estimates. Underlying net profit came in at AUD 50 million, below our forecast although this was mainly attributable to higher depreciation and interest expense on the back of the refurbishment program and large number of acquisitions. As cautioned earlier in the year, case numbers were soft during the period, reflecting an unusually low number of...
Wide-moat rated Invocare reported a soft, albeit well flagged fiscal 2018 result. Operating EBITDA declined by 4% to AUD 119 million, in line with our estimates. Underlying net profit came in at AUD 50 million, below our forecast although this was mainly attributable to higher depreciation and interest expense on the back of the refurbishment program and large number of acquisitions. As cautioned earlier in the year, case numbers were soft during the period, reflecting an unusually low number of...
Wide-moat rated Invocare reported a soft, albeit well flagged fiscal 2018 result. Operating EBITDA declined by 4% to AUD 119 million, in line with our estimates. Underlying net profit came in at AUD 50 million, below our forecast although this was mainly attributable to higher depreciation and interest expense on the back of the refurbishment program and large number of acquisitions. As cautioned earlier in the year, case numbers were soft during the period, reflecting an unusually low number of...
Despite InvoCare’s share price rising by almost 20% during the past month, the stock continues to trade at a meaningful discount to our AUD 16.00 per share fair value estimate. The company has faced several challenges and concerns during the past year including: (1) lower death rates; (2) the temporary closure of a significant portion of the funeral homes; and (3) strong competition from rival Propel Funeral Partners. We don’t think any of these issues are insurmountable, and for the most pa...
InvoCare is the Australian market leader in funeral services boasting a share of around one third. Its intangible brand assets, reputation, and scale are competitive advantages, and supportive of a wide economic moat. The number of deaths is highly predictable, creating a reliable revenue source. Historically, growth has been driven by price increases, growth in the number of deaths, small organic market share gains, and a boost from acquisitions of small private businesses at relatively low pri...
Despite InvoCare’s share price rising by almost 20% during the past month, the stock continues to trade at a meaningful discount to our AUD 16.00 per share fair value estimate. The company has faced several challenges and concerns during the past year including: (1) lower death rates; (2) the temporary closure of a significant portion of the funeral homes; and (3) strong competition from rival Propel Funeral Partners. We don’t think any of these issues are insurmountable, and for the most pa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.